BTIG Research Issues Pessimistic Forecast for Theravance Biopharma (NASDAQ:TBPH) Stock Price

Theravance Biopharma (NASDAQ:TBPH) had its price target lowered by investment analysts at BTIG Research from $40.00 to $21.00 in a report issued on Tuesday, MarketBeat reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price indicates a potential upside of 53.73% from the stock’s current price.

Several other equities research analysts also recently weighed in on TBPH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. HC Wainwright upped their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Oppenheimer started coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.60.

Theravance Biopharma Trading Down 2.1%

Shares of TBPH stock opened at $13.66 on Tuesday. The company’s fifty day simple moving average is $19.16 and its 200-day simple moving average is $16.85. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03. The company has a market cap of $692.15 million, a PE ratio of 23.96 and a beta of 0.17.

Institutional Trading of Theravance Biopharma

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after acquiring an additional 54,152 shares in the last quarter. State Street Corp increased its position in shares of Theravance Biopharma by 4.4% in the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after purchasing an additional 45,987 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Theravance Biopharma by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after purchasing an additional 40,734 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Theravance Biopharma by 12.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after purchasing an additional 92,253 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Theravance Biopharma during the third quarter worth about $10,611,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma News Summary

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company retains a strong cash runway and announced deep cost cuts — Q4 cash ~$326.5M, roughly $400M expected at end‑Q1 2026; management expects ~60% cost reduction (~$70M) and $60–70M of annualized cash flow after restructuring. This improves near‑term survival and value for remaining assets. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $27, signaling at least one analyst sees upside or acquisition/strategic outcomes that could unlock value. Read More.
• Neutral Sentiment: BTIG cut its price target from $40 to $21 but kept a “buy” rating — a mixed signal that trims optimism but still leaves upside from current levels per that firm. Read More.
• Neutral Sentiment: Board has accelerated a strategic review and is working with advisors (Lazard) to evaluate alternatives, including a possible sale — this creates near‑term uncertainty but could produce value for shareholders depending on outcome. Read More.
• Negative Sentiment: Core negative: The Phase 3 CYPRESS study of ampreloxetine missed its primary endpoint (OHSA composite), prompting the company to halt the program — this removes the company’s lead clinical value driver and was the catalyst for the sharp sell‑off. Read More.
• Negative Sentiment: B. Riley cut its price target sharply to $14 (from $28) and kept a neutral rating — another negative analyst move that reduces perceived near‑term upside. Read More.
• Negative Sentiment: Market positioning is bearish: unusually large put‑option activity was recorded (6,696 puts, ~983% above average), reflecting trader downside bets and adding selling pressure to the stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.